Integra LifeSciences Q2: Adjusted EPS $0.56 Beats, Guidance Reaffirmed, Braintree Production Begins

summarizeSummary

Integra LifeSciences reported Q2 adjusted EPS of $0.56, up from $0.45 a year ago, and reaffirmed its full-year guidance. The Braintree facility began production, supporting a planned Q4 SurgiMend relaunch.

check_boxKey Events · Earnings and Guidance · IART

• Q2 Adjusted EPS Beats

  Adjusted EPS of $0.56 vs $0.45 in Q2 2025, driven by improved gross margin (61.3% vs 60.7%) and lower operating expenses.

• Revenue Growth Modest

  Total revenue of $418.8M, up 0.8% reported and 0.7% organic. Specialty Surgery grew 1.7%, while Tissue Reconstruction declined 1.9%.

• Full-Year Guidance Reaffirmed

  Reaffirmed 2026 adjusted EPS of $2.40–$2.50 and organic revenue growth of 0.8%–3.3%. Reported revenue guidance trimmed to $1.654B–$1.695B on FX headwinds.

• Braintree Production Begins

  Manufacturing initiated at the Braintree facility, keeping the Q4 2026 SurgiMend relaunch on schedule — a critical step in resolving prior supply disruptions.

auto_awesomeAnalysis · IART · Industrial Applications And Services

Integra LifeSciences delivered a solid Q2, with adjusted EPS of $0.56 beating the prior year's $0.45 and revenue edging up 0.8% to $418.8 million. The company reaffirmed its full-year adjusted EPS guidance of $2.40–$2.50 and organic growth of 0.8%–3.3%, though it trimmed reported revenue guidance slightly on a stronger dollar. The Braintree manufacturing facility is now producing, keeping the SurgiMend relaunch on track for Q4 — a key milestone in the company's recovery from prior quality issues. With net debt at $1.6 billion and leverage at 4.1x, the balance sheet remains stretched, but improving cash flow and a stable outlook provide some reassurance.